中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 6
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(6): 1317-1322

Value of multi-glycan in the auxiliary diagnosis of dual-phenotype hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.06.019
  • 1.

    Department of Clinical Laboratory, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China

  • 2.

    Department of Laboratory Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China

Research funding:

Sponsored by Fuzhou Health Technology Project (2019-S-wq19);

Startup Fund for Scientific Research, Fujian Medical University (2019QH1296);

Fujian Provincial Natural Science Foundation Projects (general) (2020J011169)

More Information
  • Corresponding author: LIU Lijuan, ljliu@126.com (ORCID:0000-0001-9809-0056)
  • Received Date: 2021-09-27
  • Accepted Date: 2021-12-23
  • Published Date: 2022-06-20
    Abstract
  •   Objective  To investigate the expression of multi-glycan in serum of patients with dual-phenotype hepatocellular (DPHCC) and its clinical significance.  Methods  Serum samples were collected from 65 patients with DPHCC, 80 patients with primary hepatocellular carcinoma (HCC), and 120 patients with liver cirrhosis (LC) who were treated in Mengchao Hepatobiliary Hospital of Fujian Medical University from June 2019 to December 2020. DNA sequencer-aided fluorophore-assisted carbohydrate electrophoresis was used to measure the expression of N-glycan in serum, The measurement data of normal distribution were compared by t-test between the two groups and analysis of variance between multiple groups; The measurement data with non normal distribution were compared by Mann-Whitney U test between the two groups and Kruskal-Wallis H test between multiple groups, the chi-square test was used for comparison of categorical data between groups.The logistic regression method was used to establish the common index model. The efficacy of AFP, PIVKA - Ⅱ, CEA, CA19-9 and multi glycan in the diagnosis of DPHCC was evaluated by receiver operating characteristic (ROC) curve, and the area under ROC curve (AUC) was compared by Z test.  Results  There was a significant difference in multi-glycan between the DPHCC group and the HCC group (P < 0.001), while there were no significant differences in AFP, PIVKA-Ⅱ, CEA, CA19-9, and SUM between the two groups (P=0.924, 0.084, 0.442, 0.924, and 0.206). Multi-glycan had an area under the ROC curve (AUC) of 0.775, which was significantly higher than that of AFP (0.507), PIVKA-Ⅱ (0.584), CEA (0.537), CA19-9 (0.505), and SUM (0.561), and multi-glycan had a sensitivity of 69.23%, which was increased compared with the other 5 items. There were significant differences in multi-glycan, AFP, PIVKA-Ⅱ, CA19-9, and SUM between the DPHCC group and the LC group (all P < 0.001), but there was no significant difference in CEA between the two groups (P=0.14). Multi-glycan had an AUC of 0.780, which was also higher than that of AFP (0.767), PIVKA-Ⅱ (0.743), CEA (0.566), CA19-9 (0.689), and SUM (0.713), and multi-glycan had a sensitivity of 89.23%, which was increased compared with the other five items.  Conclusion  Multi-glycan can be used as one of the indicators for the auxiliary diagnosis of DPHCC.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    ZHENG QL, FENG CY, LIAN YE, et al. Clinical and pathological analysis of 6 cases of diphenotypic hepatocellular carcinoma[J]. Chin J Pathol, 2020, 49(12): 1320-1322. DOI: 10.3760/cma.j.cn112151-20200319-00237.

    郑巧灵, 冯昌银, 连渊娥, 等. 双表型肝细胞癌六例临床病理学分析[J]. 中华病理学杂志, 2020, 49(12): 1320-1322. DOI: 10.3760/cma.j.cn112151-20200319-00237.
    [2]
    WANG H, CONG WM. Research progress on clinicopathology in dual-phenotype hepatocellular carcinoma[J]. Chin J Clin Oncol, 2017, 44(12): 616-619. DOI: 10.3969/j.issn.1000-8179.2017.12.071.

    王瀚, 丛文铭. 双表型肝细胞癌新亚型的临床病理学研究进展[J]. 中国肿瘤临床, 2017, 44(12): 616-619. DOI: 10.3969/j.issn.1000-8179.2017.12.071.
    [3]
    Chinese Society of Liver Cancer, Chinese Anti-Cancer Association, Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Pathology, Chinese Anti-Cancer Association, et al. Evidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer in China(2015 update)[J]. J Clin Hepatol, 2015, 31(6): 833-839. DOI: 10.3969/j.issn.1001-5256.2015.06.004.

    中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 临床肝胆病杂志, 2015, 31(6): 833-839. DOI: 10.3969/j.issn.1001-5256.2015.06.004.
    [4]
    FANG M, GAO CF. Glycosylation and biomarkers in primary liver cancer[J]. Chin J Lab Med, 2016, 39(2): 73-75. DOI: 10.3760/cma.j.issn.1009-9158.2016.02.001.

    房萌, 高春芳. 糖基化与原发性肝癌标志物[J]. 中华检验医学杂志, 2016, 39(2): 73-75. DOI: 10.3760/cma.j.issn.1009-9158.2016.02.001.
    [5]
    HUANG C, FANG M, FENG H, et al. N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: A large-scale multicenter study[J]. Int J Cancer, 2021, 149(3): 717-727. DOI: 10.1002/ijc.33564.
    [6]
    HUANG C, LIU L, WANG H, et al. Serum N-glycan fingerprint nomogram predicts liver fibrosis: A multicenter study[J]. Clin Chem Lab Med, 2021, 59(6): 1087-1097. DOI: 10.1515/cclm-2020-1588.
    [7]
    National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.

    中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
    [8]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [9]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [10]
    GUAN W, GAO Z, HUANG C, et al. The diagnostic value of serum DSA-TRF in hepatocellular carcinoma[J]. Glycoconj J, 2020, 37(2): 231-240. DOI: 10.1007/s10719-019-09906-x.
    [11]
    LI T, MO C, QIN X, et al. Glycoprofiling of early gastric cancer using lectin microarray technology[J]. Clin Lab, 2018, 64(1): 153-161. DOI: 10.7754/Clin.Lab.2017.170814.
    [12]
    WANG Z, LIU H, YAN Y, et al. Integrated proteomic and N-Glycoproteomic analyses of human breast cancer[J]. J Proteome Res, 2020, 19(8): 3499-3509. DOI: 10.1021/acs.jproteome.0c00311.
    [13]
    TANAKA T, YONEYAMA T, NORO D, et al. Aberrant N-Glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas[J]. Int J Mol Sci, 2017, 18(12): 2632. DOI: 10.3390/ijms18122632.
    [14]
    BEDNARSKA NG, WREN BW, WILLCOCKS SJ. The importance of the glycosylation of antimicrobial peptides: natural and synthetic approaches[J]. Drug Discov Today, 2017, 22(6): 919-926. DOI: 10.1016/j.drudis.2017.02.001.
    [15]
    MARTINEZ MR, DIAS TB, NATOV PS, et al. Stress-induced O-GlcNAcylation: An adaptive process of injured cells[J]. Biochem Soc Trans, 2017, 45(1): 237-249. DOI: 10.1042/BST20160153.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (319) PDF downloads(30) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return